Athira Pharma downgraded by BTIG Research
$ATHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BTIG Research downgraded Athira Pharma from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 → $0.50 | Outperform → Neutral | Mizuho |
| 9/4/2024 | Buy → Neutral | Rodman & Renshaw | |
| 9/4/2024 | Buy → Neutral | BTIG Research | |
| 9/4/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/19/2024 | $22.00 | Buy | Rodman & Renshaw |
| 10/17/2022 | $20.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 7/7/2022 | $6.00 | Buy | Mizuho |
| 6/23/2022 | $36.00 → $5.00 | Buy → Hold | Stifel |